Comparison of the Generation of Pancreatic Cancer Patient-Derived Organoids by Endoscopic Ultrasound-Guided Fine Needle Aspirations and Fine Needle Biopsies

Aims The prognosis for pancreatic cancer remains poor. Molecular diagnostics and customized therapies are becoming increasingly important in clinical routine. Patient-derived, predictive model systems such as organoids of endoscopic ultrasound (EUS)-guided punctures have the potential to substantially increase the depth of information from biopsy material by functional and molecular characterization of pancreatic cancer-patient derived organoids (PDOs). Improving the take rate of these organoids is a key step to bring this technology into routine clinical diagnostics.